UK Study Assessing Flexible Dose Fesoterodine in Adults

Urinary Bladder, Overactive Clinical Trial

— SAFINA  

Official title:

A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00806494
• Other study ID #: A0221058
• Status: Completed
• Phase: Phase 4
• First received: December 9, 2008
• Last updated: January 4, 2011
• Start date: February 2009
• Est. completion date: January 2010

Study information

• Verified date: January 2011
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To explore the effects of fesoterodine when used in a flexible dose manner

Recruitment information / eligibility

• Status: Completed
• Enrollment: 331
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female >18 years old

• OAB for >3 months

Exclusion Criteria:

• Patients with conditions that would contraindicate for fesoterodine use

• Patients with significant hepatic and renal disease or other significant unstable diseases.

• OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Urinary Bladder, Overactive

Intervention

Drug:
• Fesoterodine
Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated

Locations

Country	Name	City	State
United Kingdom	Pfizer Investigational Site	Addlestone	Surrey
United Kingdom	Pfizer Investigational Site	Ashford	Middlesex
United Kingdom	Pfizer Investigational Site	Ayrshire	Scotland
United Kingdom	Pfizer Investigational Site	Baillieston	Glasgow
United Kingdom	Pfizer Investigational Site	Bath	Somerset
United Kingdom	Pfizer Investigational Site	Bath
United Kingdom	Pfizer Investigational Site	Bath
United Kingdom	Pfizer Investigational Site	Bexhill on Sea	East Sussex
United Kingdom	Pfizer Investigational Site	Blackpool	Lancashire
United Kingdom	Pfizer Investigational Site	Blackpool	Lancashire
United Kingdom	Pfizer Investigational Site	Bradford-on-Avon	Wiltshire
United Kingdom	Pfizer Investigational Site	Bristol
United Kingdom	Pfizer Investigational Site	Bucks
United Kingdom	Pfizer Investigational Site	Chesterfield	Derbyshire
United Kingdom	Pfizer Investigational Site	Chesterfield	Derbyshire
United Kingdom	Pfizer Investigational Site	Chippenham	Wilts
United Kingdom	Pfizer Investigational Site	Crewe	Cheshire
United Kingdom	Pfizer Investigational Site	Doncaster	South Yorkshire
United Kingdom	Pfizer Investigational Site	Ely	Cambridgeshire
United Kingdom	Pfizer Investigational Site	Falkirk	Scotland
United Kingdom	Pfizer Investigational Site	Fowey	Cornwall
United Kingdom	Pfizer Investigational Site	Glasgow
United Kingdom	Pfizer Investigational Site	Hertfordshire
United Kingdom	Pfizer Investigational Site	Hinckley	Leicestershire
United Kingdom	Pfizer Investigational Site	Leatherhead	Surrey
United Kingdom	Pfizer Investigational Site	London
United Kingdom	Pfizer Investigational Site	London
United Kingdom	Pfizer Investigational Site	Mortimer	Reading
United Kingdom	Pfizer Investigational Site	Northants
United Kingdom	Pfizer Investigational Site	Northwood	Middlesex
United Kingdom	Pfizer Investigational Site	Penzance	Cornwall
United Kingdom	Pfizer Investigational Site	Plymouth	Devon
United Kingdom	Pfizer Investigational Site	Plymouth
United Kingdom	Pfizer Investigational Site	Sheffield	South Yorkshire
United Kingdom	Pfizer Investigational Site	Swansea
United Kingdom	Pfizer Investigational Site	Swindon
United Kingdom	Pfizer Investigational Site	West Didsbury	Manchester
United Kingdom	Pfizer Investigational Site	Winterton	Scunthorpe
United Kingdom	Pfizer Investigational Site	Worthing	West Sussex

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12	The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, more specifically (ie), a decrease in number of micturitions relative to baseline=improvement.	Baseline, Week 12	No
Secondary	Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4	The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of micturitions relative to baseline=improvement.	Baseline, Week 4	No
Secondary	Percentage Change From Baseline in the Number of Micturitions Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in micturitions was calculated as change in mean number of micturitions per 24 hours at that visit divided by the baseline mean number of micturitions per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12	Nocturnal micturitions were defined as those occurring between the time the subject went to bed and the time he or she arose to start the next day. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of nocturnal micturitions relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in nocturnal micturitions was calculated as change in mean number of nocturnal micturitions per 24 hours at that visit divided by the baseline mean number of nocturnal micturitions per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 4 and 12	UUI episodes were defined as those with a Urinary Sensation Scale (USS) rating of 5 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).; Mean number of UUI episodes per 24 hours was calculated as total number of micturitions with USS rating of 5 divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of UUI episodes relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Percentage Change From Baseline in UUI Episodes Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in UUI episodes was calculated as change in mean number of UUI episodes per 24 hours at that visit divided by the baseline mean number of episodes per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 4 and 12	Urgency episodes were defined as those with a USS rating of >=3 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of urgency episodes per 24 hours was calculated as total number of urgency episodes divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of urgency episodes relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Percentage Change From Baseline in Urgency Episodes Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in urgency episodes was calculated as change in mean number of urgency episodes per 24 hours at that visit divided by the baseline mean number of urgency episodes per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Nocturnal Urgency Episodes (NUEs) Per 24 Hours at Weeks 4 and 12	NUEs were defined as those with a USS rating of >=3 in the diary, occurring between the time the participant goes to bed and the time he/she arises to start the next day. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).; Mean number of NUEs per 24 hours was calculated as total number of NUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of NUEs relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Percentage Change From Baseline in NUEs Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in NUEs was calculated as change in mean number of NUEs per 24 hours at that visit divided by the baseline mean number of NUEs per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Severe Urgency Episodes (SUEs) Per 24 Hours at Weeks 4 and 12	SUEs were defined as those with a USS rating of >=4 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of SUEs per 24 hours was calculated as total number of SUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of SUEs relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Percentage Change From Baseline in SUEs Per 24 Hours at Weeks 4 and 12	Percentage change from baseline in SUEs was calculated as the change in mean number of SUEs per 24 hours at that visit divided by the baseline mean number of SUEs per 24 hours, multiplied by 100.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Mean Number of Incontinence Pads Used Per 24 Hours at Weeks 4 and 12	The mean number of incontinence pads used per 24 hours was calculated as the total number of incontinence pads used divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of incontinence pads used relative to baseline=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Weeks 4 and 12	PPBC: self-administered, single-item, questionnaire to describe perception of participants bladder-related problems (rated on 6-point scale: 1=no problems at all, 2=some very minor, 3=some minor, 4=some moderate, 5=severe, 6=many severe problems). Score change=score at observation minus score at baseline; re-scaled to 4-point categorical variables (major improvement [score difference <=-2]; minor improvement [score difference =-1]; no change [score difference = 0]; deterioration [score difference >=1]), based on PPBC score.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Urgency Perception Scale (UPS) at Weeks 4 and 12	UPS: self-administered, single-item questionnaire to measure participant's perception of urinary urgency (rated on 3-point scale: 1=usually not able to hold urine; 3=usually able to finish what I am doing before going to toilet without leaking). Score change=score at observation minus score at baseline; re-scaled to 3-point categorical variables (improvement [Increase of 1 or more points in difference of scores]; no change [score difference=0]; deterioration [Negative difference of scores], based on UPS score, with number of participants in each of the 3-point categories.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Weeks 4 and 12	OAB-q symptom bother scale (8 items) is part of the OAB-q. Symptom bother score=sum of scores for items 1 to 8 (each symptom bother item measured on 6-point Likert scale ranging from 1 (not at all) to 6 (a very great deal). Lowest possible raw score=8; highest possible score=48. Data analyzed based on transformation of score to a 0 to 100 scale: (Actual total raw score - lowest possible value of raw score)/raw score range * 100. 0=no symptom bother, 100=high symptom bother. Change=mean score at observation minus mean score at baseline, negative change in score=improvement.	Baseline, Week 4 and Week 12	No
Secondary	Change From Baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Score at Week 12	ICIQ-SF: self-administered questionnaire for assessment and quantification of incontinence and its impact on quality of life. ICIQ score=sum of the responses to 3 questions: How often do you leak urine? (range: 0=never to 5=all the time); How much urine do you usually leak? (range: 0=none to 6=a large amount); Overall, how much does leaking urine interfere with your everyday life? (range: 0=not at all to 10=a great deal). Score range=0 (low bother from urine leakage) to 21 (maximum bother). Negative change (decrease) from baseline in score value=reduced level of bother.	Baseline, Week 12	No
Secondary	Number of Participants With Each Categorical Response at Week 12 for Benefit, Satisfaction and Willingness to Continue (BSW) Questionnaire	BSW: 3-item questionnaire to assess participants perception of effect of treatment in terms of treatment benefit, satisfaction with treatment, and participants willingness to continue treatment. Response to each item recorded in dichotomous fashion (Benefit: yes/no, yes - little benefit/much benefit; Satisfaction: yes/no, yes - a little satisfied/very satisfied, no - a little dissatisfied/very dissatisfied; Willingness to continue: yes/no, yes - a little bit willing/very willing, no - a little unwilling/very unwilling).	Week 12 (or Early Withdrawal)	No
Secondary	Percentage of Participants Reporting Satisfaction on the Treatment Satisfaction Questionnaire (TSQ) at Week 12	TSQ: Independent component of the overactive bladder TSQ. Self- administered, 1-item measure of participant satisfaction for participants receiving treatment for OAB. The 5 categorical responses were grouped to 'Satisfied' (including 'very satisfied' and 'somewhat satisfied') and 'Dissatisfied' (including 'very dissatisfied','somewhat dissatisfied', and 'neither dissatisfied nor satisfied'). Percentage of participants reporting satisfaction included those with categorical responses of 'very satisfied' and 'somewhat satisfied'.	Week 12 (or Early Withdrawal)	No
Secondary	Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores at Week 12	KHQ: Self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, severity of urinary symptoms). Each domain was a categorical scale that was converted to a numeric score. All domains transformed to a range of 0 to 100, where 0=best outcome/response and 100=worst outcome/response. Change=mean score at Week 12 minus mean score at baseline, negative change from baseline=improvement.	Baseline, Week 12	No

External Links

•   To obtain contact information for a study center near you, click here.